The landscape of intellectual property law, particularly in the biopharma industry, continues to rapidly evolve with technological advancements and legislative reforms. Kilpatrick Townsend recently held its semi-annual KTIPS (Kilpatrick Townsend Intellectual Property Seminar) in San Francisco, where firm attorneys led interactive discussions on these developments.
Among the key topics discussed at KTIPS were enablement, written description, Section 101 challenges and the recent Patent Eligibility Restoration Act of 2023 which promises to influence the biopharma patent dynamics significantly. According to the seminar, here are the five main takeaways from these discussions.
- Enablement: The strict criteria for demonstrating enablement continue to pose challenges for biotech companies, particularly in precision medicine and genomic editing where full spectrum enablement remains an arduous, often insurmountable task.
- Written Description: The requirement for a ‘written description’ is now more than ever being invoked in biopharma patent disputes as a ground for invalidating patents. This poses significant concerns.
Celebrate everyday heroes in public schools everywhere. - Section 101 Challenges: Section 101 of the U.S. Patent Act with its strict criteria on the patent-eligible subject matter continues to present significant hurdles in the path of patenting biotechnological inventions.
- The Patent Eligibility Restoration Act of 2023: The recently introduced legislative reform has opened new avenues by modulating the patent eligibility criteria. It promises to lend more predictability to patent prosecution processes while helping foster innovation in the biopharma industry.
- The impact of these developments on business landscape and potential challenges/opportunities was discussed as well. Emphasis was placed on the need for possible legislative reforms to adequately protect biopharma inventions while fostering innovation.
This is a rapidly evolving discipline and it’s crucial that legal and IP professionals within the biopharma industry stay abreast of ongoing legal changes and legislative reforms to ensure they protect their patent portfolio and adapt to the changing legal landscape. regular updates from forums such as the KTIPS can play a key role in making this possible.